Literature DB >> 11082443

Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia.

R R Metzger1, H M Haughey, D G Wilkins, J W Gibb, G R Hanson, A E Fleckenstein.   

Abstract

Single and multiple high-dose administrations of methamphetamine (METH) differentially decrease dopamine (DA) transporter (DAT) function, as assessed by measuring [(3)H]DA uptake into rat striatal synaptosomes prepared 1 h after treatment. Prevention of METH-induced hyperthermia attenuated the decrease in DAT activity induced by multiple injections of the stimulant. Likewise, this decrease was attenuated by previous depletion of striatal DA levels using alpha-methyl-p-tyrosine (alphaMT) or pretreatment with the D1 and D2 antagonists SCH-23390 and eticlopride, respectively. However, METH-induced hyperthermia was also blocked by alphaMT and eticlopride. Reinstatement of hyperthermia to alphaMT- or eticlopride-pretreated rats partially restored the METH-induced decrease in DAT activity. In contrast, neither prevention of METH-induced hyperthermia depletion of DA, nor DA antagonists altered the decrease in DAT function induced by a single administration of METH. Pretreatment with the antioxidant N-t-butyl-alpha-phenylnitrone prevented part of the decrease in DAT function associated with multiple, but not a single, METH injections. Although not tested directly, additional data presented here suggest that the reduction in DAT activity induced by a single METH administration constitutes a part of the total reduction observed immediately after multiple administrations. Taken together, the results indicate that DA, hyperthermia, and oxygen radicals contribute to a component of the rapid decrease in DAT function induced by multiple injections of METH but do not appear to be associated with the reduction induced by a single administration of the stimulant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082443

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

2.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

Review 3.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

4.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

5.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

Review 6.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.

Authors:  Evan L Riddle; Annette E Fleckenstein; Glen R Hanson
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

7.  Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.

Authors:  Christopher L German; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2012-08-23       Impact factor: 5.372

Review 8.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

9.  Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Authors:  Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen A Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

10.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.